These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 24991839)

  • 1. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
    Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
    Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
    Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
    Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
    Mehnert JM; Kaveney AD; Malhotra J; Spencer K; Portal D; Goodin S; Tan AR; Aisner J; Moss RA; Lin H; Bertino JR; Gibbon D; Doyle LA; White EP; Stein MN
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):899-907. PubMed ID: 31463691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
    Chi KH; Ko HL; Yang KL; Lee CY; Chi MS; Kao SJ
    Oncotarget; 2015 Jun; 6(18):16735-45. PubMed ID: 25944689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
    Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
    Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
    Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
    Hong DS; Kurzrock R; Falchook GS; Andresen C; Kwak J; Ren M; Xu L; George GC; Kim KB; Nguyen LM; O'Brien JP; Nemunaitis J
    Oncotarget; 2015 Dec; 6(40):43127-34. PubMed ID: 26503473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
    Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
    J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
    Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H
    Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
    Plummer R; Stephens P; Aissat-Daudigny L; Cambois A; Moachon G; Brown PD; Campone M
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):257-65. PubMed ID: 24880570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
    Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide and cisplatin in avdanced malignant melanoma.
    Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
    Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
    Rubie H; Geoerger B; Frappaz D; Schmitt A; Leblond P; Ndiaye A; Aerts I; Le Deley MC; Gentet JC; Paci A; Chastagner P; Dias N; Djafari L; Pasquet M; Chatelut E; Landman-Parker J; Corradini N; Vassal G
    Eur J Cancer; 2010 Oct; 46(15):2763-70. PubMed ID: 20558056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.